nrxp investor relations

NRX Pharmaceuticals Inc Ordinary Shares NRXP Stock Analysis Morningstar Rating | Rating as of Sep 5, 2022 Quote Chart Stock Analysis News Price vs Fair Value Sustainability Trailing Returns. Investor Relations We are a growth-oriented limited partnership. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Our focus is to invest in system solutions that will drive long-term, profitable growth, superior free cash flow and robust capital returns to our owners. NRXP 14.81% DJIA -0.24% Russell 2K 0.25% Health Care/Life Sciences 0.11% Overview Per-Share Earnings, Actuals & Estimates NRX Pharmaceuticals Inc. Quarterly Annual Actual Analyst Range. CORPORATE CONTACT Johnson Controls and the Asthma and Allergy Foundation of America Advocate for Healthier Infinity Stone Provides Update on Rockstone Drill Program and Corporate Update. Investors. A replay will be available following the call on the Company's website. Trending now. Stocks Rankings for NRXP. Our focus is on the future, and the future of power begins with the consumer. Copyright 2022 NextEra Energy Partners, LP. 3rd Party Ad. A live webcast of the conference call will be available on the Company's website at: NRx Pharmaceuticals Third Quarter 2022 Earnings Call. DOW 0.00%. NextEra Energy Partners acquires, manages and owns contracted clean energy projects with stable, long-term cash flows. Find out more about NXP's long-term strategy and Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or internationally +1 (412) 317-1837. Contact 1201 Orange Street, Suite 600 Wilmington,. NextEra Energy Partners, LP third-quarter 2022 financial results available on NextEra Energy Partners, LP declared quarter distribution, Third Quarter 2022 NextEra Energy, Inc. and NextEra Energy Partners, LP Conference Call, NextEra Energy and NextEra Energy Partners at the Wolfe Research Utilities, Midstream & Clean Energy Conference, NextEra Energy and NextEra Energy Partners at Barclays CEO Energy-Power Conference. 2,234 Day's Range - 52-Week Range $0.49 - $26.24 Dividend & Yield N/A (N/A) NRXP Stock Predictions, Articles,. NASDAQ 0.00%. (132.58% Upside) Based on 1 Wall Street analysts offering 12 month price targets for NRX Pharmaceuticals in the last 3 months. Above figures based on trailing 12-month performance (US $). data. Vol.) Cookies are used to offer you a better browsing experience and to analyze our traffic. It is interesting and ironic that this all, Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome, Apple Supplier GoerTek Dives for Second Consecutive Day, AWS fhrt neue Infrastrukturregion in der Schweiz ein, NIO Inc. Reports Unaudited Third Quarter 2022 Financial Results, UPLIFT NOW ACCEPTED THROUGH ARC PAY, SUPPORTED BY UATP, October Inflation Report to Outline Latest Price Trends -- Commodities Roundup, Veru Shares Plunge Premarket After Negative FDA Panel Vote, Becton Dickinson Forecasts Lower 2023 Sales, Becton Dickinson 4Q Sales Fall as Covid-Test Demand Wanes, Becton Dickinson Raises Quarterly Dividend by 4.6%, UK Sells GBP3.5 Billion in January 2027 Gilt, North American Morning Briefing: Crucial Inflation Data Looms, European Midday Briefing: Mood Dims Ahead of U.S. CPI, ArcelorMittal 3Q Profit Missed Views as Shipments Fell, Energy Costs Hit -- Update, FTSE 100 Falls as Traders Digest Earnings, UK House Price Data May Question Bets on BOE Rate Rises. During the day the stock fluctuated 8.62% from a day low at $0.87 to a day high of $0.95. --Company to Host Conference Call November 14, 2022, at 8:00AM ET---. business outlook from the NXP management team. Total 'capital returned to shareholder consists of dividends paid and shares repurchased. It is the first oral drug to target suicidal bipolar depression, a significant unmet medical need, as it is estimated that approximately 50% of the 7 million individuals with bipolar disorder in the U.S. attempt suicide over their lifetime, mostly during the depressive phases. Price Area Volume: Previous Close - Market Cap - PE Ratio - EPS - Volume (Avg. Trending now. View corporate profile>> Insperity announces Second Quarter 2022 Earnings Download Company Guidance for the third quarter and full year 2022 Long Tail Down.. Nrx is getting destroyed again today. We will not release or resell your information to third parties without your permission. NIO Inc. Reports Unaudited Third Quarter 2022 Financial Results. Subscribe to receive news on financial results, investor events and SEC filings, direct to your inbox. https://stockcharts.com/freecharts/gallery.html?NRXP I just wondering, No, I suspect that eventually we'll be flirting. A Diversified Natural Resource Company Natural Resource Partners L.P. is a diversified natural resource company that owns, manages and leases a diversified portfolio of properties in the United States, including coal, industrial minerals and other natural resources, as well as rights to conduct carbon sequestration and renewable energy activities. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Customize your views and export NRX-101 is one of the first oral antidepressants currently in late-stage clinical studies targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, as well as PTSD and other indications. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Nov. 7, 2022, 06:47 AM. With Prime Featured, display your headline and ticker symbol on the pages where our users live. Molly Cogan . 1201 ORANGE STREET SUITE 600, WILMINGTON, Delaware, 19801, United States +1 484 254-6134 https://nrxpharma.com. RADNOR, Pa., Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that. NRx boldly addresses the life-threatening diseases facing the world today that often go untreated - by researching, developing, and scaling solutions to help people who most desperately need them. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies with the . All rights reserved. 2006-2020 NXP Semiconductors. Sr. Director, Global Communications Based on the results of a Phase 2 proof-of-concept study, NRX-101 received Breakthrough Therapy Designation from the FDA for the treatment of severe bipolar depression in patients with ASIB after initial stabilization with ketamine or other effective therapy. Not an offer or recommendation by Stocktwits. Log In. U.S. News compares companies to their industry peers based on a variety of company fundamentals, performance metrics and investor preferences to help you find the right . All rights reserved. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. NRXP Stock Price Prediction. Receive SEC filings, Events, Press Releases and Stock Price Alerts. Close price at the end of the last trading day (Thursday, 3rd Nov 2022) of the NRXP stock was $0.89. Esq. By providing my email, I consent to receiving investment related electronic messages from Stockhouse. PSFE. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail. REGAL REXNORD CORPORATION REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Sales Up 52% Versus PY And Up 12% On An Organic Basis Daily Orders Down 2% In 2Q Versus PY On A Pro Forma Basis Backlog Up Over 50% Versus Beginning of 2021; Book-To-Bill Above One For Prior 7 Quarters, Averaging 1.10 In 2021 and 1.05 In 1H 2022 Real-time trade and investing ideas on NRX Pharmaceuticals Inc NRXP from the largest community of traders and investors. Information originally presented at our NXP Investor Day NRX Pharmaceuticals Inc 0.88 0.05 (6.61%) Watch. market share positions within our target markets, enabling our customers' success. The price has risen in 5 of the last 10 days and is up by 20.47% over the past 2 weeks. En cliquant sur Refuser tout, vous refusez tous les cookies non essentiels et technologies similaires, mais Yahoo continuera utiliser les cookies essentiels et des technologies similaires. Stretch Your Dollar: Five ways to boost your credit Video. Investor Relations Insperity, a trusted advisor to America's best businesses for more than 30 years, provides an array of human resources and business solutions designed to help improve business performance. NRX-101 is now manufactured via a commercial-stage process. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above. NTOIY. NRXP; NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022; Trending News. This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. NRX-101 is an investigational treatment for bipolar depression in patients with Acute and Sub-Acute Suicidal Ideation and Behavior (ASIB, SSIB) Read more. Our financial statements are records of our financial activity. En cliquant sur Accepter tout, vous acceptez que Yahoo et nos partenaires traitent vos informations personnelles et utilisent des technologies telles que les cookies pour afficher des publicits et des contenus personnaliss, et des fins de mesure des publicits et des contenus, dtude des audiences et de dveloppement de produit. AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. Conference Call and Webcast Details. NRx Pharmaceuticals expects to begin its registration trial for NRX-101 under a SPA in 4Q 2022 or early Q1/2023. We are a growth-oriented limited partnership. on very, So big pharma Pfizer received an emergency use, GoodStick, Very Much Agreed. Investor Help Forum; iHub NewsWire Bluegreen Vacations Holding Corporation Announces Intention to Commence a Cash Tender Offer for . Sign Up. Financial Market Data powered by QuoteMedia. NRx Pharmaceuticals, Inc. (NRXP) has two Phase III assets for which it has Fast Track and Breakthrough Therapy designation, respectively: intravenous ZYESAMI for Critical COVID-19 and NRX-101 for bipolar depression with suicidality. Access NXP historical financial results, ESG data and Slectionnez Grer les paramtres pour grer vos prfrences. RADNOR, Pa., Nov. 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company . NRXP Investor Analysis Under 35 0.0% Last 30 days Holdings Change 10.0% of NRXP holders are under 35 Average Segment Performance Average P/E Ratio17.61 Beta1.24 Dividend Yield4.32% Between 35-55 9.7% Last 30 days Holdings Change 73.3% of NRXP holders are between 35-55 Average Segment Performance Average P/E Ratio16.83 Beta1.27 Dividend Yield4.84% radnor, pa., nov. 9, 2022 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp), ("nrx pharmaceuticals" or the "company"), a clinical-stage cns biopharmaceutical company, today announced the release of the first batches manufactured in the u.s. of nrx-101, its phase 3-ready investigational drug, targeting suicidal bipolar depression and with NRXP shares are trading up $0.05 today. CORPORATE CONTACT Molly Cogan Sr. Director, Global Communications mcogan@nrxpharma.com INVESTOR RELATIONS Suzanne Messere Investor Relations Dive deeper into our financial activities, how we conduct our operations and our sustainability goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management. Clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect. NIO. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. DOW 0.00%. Up to 50% of individuals with bipolar disorder attempt suicide over their lifetime, and estimates indicate that up to 20% may succumb to suicide. NXPs strategy continues to focus on strong corporate governance and innovative system solutions that enable our customers success and drive long-term, profitable growth Our sustainability reporting reflects our operations impact, social engagements and product innovations. $12.35B Revenue $3.38B Cash flow from operations $3.13B Please go to the link in the email message to retrieve your password. Access IR contact details to get in touch. An email was sent with password retrieval instructions. or his Investor . Vous pouvez modifier vos choix tout moment en consultant vos paramtres de vie prive. Our goal is to attain high relative Find the latest SEC Filings data for NRX Pharmaceuticals, Inc. Common Stock (NRXP) at Nasdaq.com. Relief's management team strategy is to maintain a lean internal structure and a series of collaborations with relevant worldwide experts. NRx Pharmaceuticals to Host Conference Call & Webcast, Stockhouse.com is owned by Stockhouse Publishing Ltd. 2019 Stockhouse Publishing Ltd. All rights reserved. Rooms Rankings Earnings Newsletters. Our transformed business is best positioned to grow market share through capitalizing on emerging trends and disruptive technologies. The management team works collectively to execute all duties traditionally assigned to a CEO. (held Nov 11, 2021). NRXP; NRXPW Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies NRx Pharmaceuticals, Inc. Investors of Class Action and Lead Plaintiff Deadline: March 21, 2022 . A live webcast of the conference call will be available on the Company's website at: NRx Pharmaceuticals Third Quarter 2022 Earnings Call. Looking Towards a Nuclear Solution to Solve Clean Energy Problems and Accelerate Decarbonization, Logiq Signs A New Contract, estimated to generate $2-$3 million in revenue per month going forward, Worldwide Crypto Based Exchange Traded Products AUM Rose 7.5% in October, Lithium Market Still Heating Up As End-Users Scramble for New Supply, Cardiol Therapeutics Announces Study Results at The American Heart Association Scientific Sessions 2022, What Psychedelics Can Do Is Actually Heal You So That Your Brain Is Operating Differently, Metal Energy Updates on the 10,000 Metre Drill Program on its Manibridge High-Grade Nickel Project, Final Drilling of 2022: The Top Drill Programs Closing Out the Year Free Insights Report Here, Autonomous Drone-In-a-Box solution supports SpaceX Starlink Satellite Communications, Leading-edge technology provides aviation safety, preventative measures, and predictive capabilities, Calima Energy: An environmentally responsible gas & oil producer, X-Terra Resources offers exciting lithium opportunity, CardiolRx study demonstrates protective effects vs. acute pericarditis, This e-commerce merger could be an industry game changer, Sirios (TSXV:SOI) intersects gold at surface & extends mineralization of the Cheechoo deposit, RecycLiCo (TSXV:AMY) advances to lithium recovery stage of demonstration plant project, VPN Technologies (CSE:VPN) subsidiary enters prototype phase & trials, Krakens (TSXV:PNG) PanGeo Subsea concludes $5M+ of sub-bottom imager projects, ALX Resources (TSXV:AL) samples nickel, copper, & cobalt at the Flying Vee Project, Patriot One Technologies (TSX:PAT) expands partnership with Oak View Group. NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company . NRX-101 is a patented, oral, fixed dose combination of D-cycloserine and lurasidone. Management will host the call, followed by a question-and-answer period. 3rd Party Ad. This is 2.86% less than the trading day before Wednesday, 2nd Nov 2022. During the last trading day the stock fluctuated 18.75% from a day low at $0.80 to a day high of $0.95. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. Stockhouse membership requires an email address which must be shared by Facebook. Real-time trade and investing ideas on NRX Pharmaceuticals Inc NRXP from the largest community of traders and investors. By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically. Suzanne Messere Investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company's investor relations representative at egoldstein . S&P 500 0.00%. Based on analysts offering 12 month price targets for NRXP in the last 3 months. If you are aware of any facts relating to this investigation, or purchased NRx shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/nrxp. Semiconductors are entering a new cycle of growth driven by in-car electronics, AI-IoT devices, cloud processing, automation, 5G and connectivity features that make the world smarter and Log In. If, All good succinct questions Joe, but who knows, And the DUMPER of roughly EIGHT MILLION Shares, Uh-oh, looks like some heavy hitters are bailing. RADNOR, Pa., Nov. 7, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals" or the "Company"), a clinical-stage CNS biopharmaceutical company, today announced that it has obtained approximately $11 million in unsecured debt financing (the "Note") from Streeterville Capital, LLC, a Utah limited liability company. Inhaled aviptadil for the possible treatment of COVID-19, Be careful if holding a short position,if news, Be careful on these stocks below $1 moving, NRx Pharmaceuticals Provides Update on Breakthrough Therapy Designation, Wednesday, JJ bought 100,000 shares (@ 0.58) of, After receiving the latest NRX news release regarding, Things do NOT add up regarding the stated, Instead Something is up. additional big cheese are, At this low low price, insiders sb buying, Someone told me this stock. Our goal is to attain high relative market share positions within our target markets, enabling our customers' success. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. They include a balance sheet, income statements, statement of cash flow and statement of retained earnings. Since 2020, Relief has added senior executives with extensive experience in finance, commercialization, medical . NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be. Premium Featured gets you a step above: Your logo + Your Headline + Your Ticker + Our Audience = Perfection. Sign Up. Nous, Yahoo, faisons partie de la famille de marques Yahoo. Cancel. We conduct our operations in accordance with our Code of Conduct. Top Stories By continuing to use our service, you agree to our use of cookies. Cancel. suzanne.messere@sternir.com, View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-third-quarter-2022-results-on-november-14-2022-301674138.html, Get the latest news and updates from Stockhouse on social media, Stockhouse.com uses cookies on this site. NRX Pharmaceuticals Inc (NRXP) Message Board - Company Name: NRX Pharmaceuticals Inc, Stock Symbol: NRXP, Industry: Biotechs - Total Posts: 888 - Last Post: 09/21/2022 10:31:53 AM - company/specific stock board. Cautionary Note Regarding Forward-Looking Statements. mcogan@nrxpharma.com, INVESTOR RELATIONS and shareholder value.. NRX Pharmaceuticals Inc 0.88 0.05 (6.61%) Watch. You must be logged in to give a plus1 award. or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. and Human Trafficking Statement, Kurt Sievers, President and CEO, NXP Semiconductors. The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation & behavior (ASIB) remains electroconvulsive therapy (ECT). RADNOR, Pa., Nov. 10, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage, biopharmaceutical company today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022. We leverage proven science and clinical expertise to identify and apply medical solutions as immediately as possible, while simultaneously focusing on expanding therapeutic potential for the [] The average price target represents a 132.58% change from the last price of $0.86. Rooms Rankings Earnings Newsletters. However, if mediation prevents the, PW, please consider that any mediation progress does, choo, Progress with median has been reported!! Hopefully, but, At this point, simply doing the right and, new lows continue for NRXP and insiders are, HeadlineI would have preferred a headline stating that, This should have been the headline for NRXP, JKvery, very true. RADNOR, Pa., Nov. 9, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), ("NRx Pharmaceuticals" or the "Company"), a clinical . Our focus is to invest in system solutions that will drive long-term, profitable growth, superior free cash flow and robust capital returns to our owners. https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-to-report-third-quarter-2022-results-on-november-14-2022-301674138.html, @ the Bell: Global stocks see red as midterm election results roll in, @ the Bell: Stocks rise with U.S. midterms underway, @ the Bell: TSX lifted by energy, & real estate, U.S. focused on midterms. The NRx Pharmaceuticals, Inc. stock price gained 14.81% on the last trading day (Tuesday, 1st Nov 2022), rising from $0.81 to $0.93. more sustainable. stock charts online. Company overview About NextEra Energy Partners NextEra Energy Partners, LP (NYSE: NEP) is a growth-oriented limited partnership formed by NextEra Energy, Inc. (NYSE: NEE). To enable on your browser, follow our, Access webcast and download presentations, NXP Semiconductors Reports Third Quarter 2022 Results, NXP Semiconductors Announces Conference Call to Review Third Quarter 2022 Financial Results, NXP Semiconductors Announces Quarterly Dividend, Slavery See. The company's lead program NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, targets the brain's NMDA receptor and is being investigated in a Phase 3 trial under an FDA Special Protocol Agreement and Breakthrough Therapy Designation in patients with bipolar depression and suicidal ideation, an indication for which the only approved treatment is electroshock therapy. S&P 500 0.00%. $2.00. Year Date Event Location; 2022: Nov 29: Credit Suisse Annual Technology Conference: Scottsdale, AZ: 2022: Nov 30: Wells Fargo Annual TMT Summit: Las Vegas, NV NRx Pharmaceuticals Third Quarter 2022 Earnings Call. Today, no medicine is approved to treat patients with bipolar depression suffering suicidal ideation. The company will host a conference call and webcast on November 14, 2022, 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. Headquartered in Juno Beach, Florida, NextEra Energy Partners owns interests in wind and solar projects in the U.S. as well as natural gas infrastructure assets in Texas and Pennsylvania. View the. Transfer Agent Empire Stock Transfer, Inc. 1859 Whitney Mesa Drive Henderson, NV 89014 T: 702-818-5898 52 Week Range 2.38 - 48.80. in 2020 the stock was $77. Investor Relations All rights reserved. NextEra Energy Partners, LP (NYSE: NEP) is a growth-oriented limited partnership formed by NextEra Energy, Inc. (NYSE: NEE). Not an offer or recommendation by Stocktwits. Pour en savoir plus sur notre utilisation de vos informations, veuillez consulter notre Politique relative la vie prive et notre Politique en matire de cookies. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresseIP, Navigation et recherche lors de lutilisation des sites Web et applications Yahoo. We also use them to share usage information with our partners. AZORES AIRLINES, GALP, NESTE AND CARLYLE AVIATION TAKE OFF FOR SATA GROUP'S FIRST . A replay will be available following the call on the Company's website.. NRX-101 is a patented, oral fixed-dose combination of two FDA-approved drugs: D . The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Participants that are unable to join the webcast can access the conference call via telephone by dialing domestically +1 (833) 630-1956 or . NRx Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute Suicidality, a substantially broader indication. Meet our board of directors; learn about our committees and ethical reporting procedures. Short selling NRXP is an investing strategy that aims to generate trading profit from NRx Pharmaceuticals as its price is falling. For best experience this site requires Javascript to be enabled. of NRXP holders are between 35-55 Average Segment Performance Average P/E Ratio 18.88 Beta 1.33 Dividend Yield 4.56% Over 55 5.4% Last 30 days Holdings Change 16.7% of NRXP holders are over 55 Average Segment Performance Average P/E Ratio 20.54 Beta 1.13 Dividend Yield 4.18% Overview of age group and performance of NRXP stock investors The Breakthrough Therapy Designation and Special Protocol Agreement were awarded by the FDA based on the Company's prior STABIL-B trial that demonstrated substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine. PW, thanks for the colorful and interesting analogy. To date, NRX-101 is the only oral NMDA investigational medicine focused on bipolar depression in patients with acute and sub-acute suicidality. Find contact details for our investor relations team around the world. NRX-101 is a patented, oral, fixed dose combination of D-cycloserine and lurasidone, neither of which has shown addiction potential. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. NASDAQ 0.00%. Leading retail brands Providing customized solutions through a portfolio of differentiated retail brands Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.